RxDoctor Payments Data

Rossella Marmorato Rivera, MD

Cardiovascular Disease · San Juan, PRNPI 1205022795

Payments from drug & device makers

$5,924in general payments, 2019–2025

Across 52 payments — averaging $113.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • E.r. Squibb & Sons, L.L.C.$493
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$210
  • Medtronic$203
  • Boston Scientific$190
  • Amgen$184
  • plus $352 from 4 others

What the payments were for

  • Consulting fees$3,43058%
  • Travel & lodging$170%
  • Food & beverage$2,38240%
  • Education$952%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,924 in reported general payments places this provider in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$13,539
Medicare patients
36
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban238$154,095
EliquisApixaban204$133,065
FarxigaDapagliflozin Propanediol203$127,258
EntrestoSacubitril/Valsartan112$84,854
Repatha SureclickEvolocumab112$63,855
JardianceEmpagliflozin81$56,017
BrilintaTicagrelor86$47,562
Repatha SyringeEvolocumab39$22,156
Metoprolol Succinate1,569$19,832
Candesartan Cilexetil187$13,009
Rosuvastatin Calcium1,209$12,530
SynthroidLevothyroxine Sodium181$11,003
Losartan Potassium845$7,463
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid63$6,384
Atorvastatin Calcium698$5,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$181$174,820289 claims
Johnson & JohnsonXarelto$4,292$154,095238 claims
NovartisEntresto$25$84,854112 claims
Boehringer IngelheimJardiance$102$56,01781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →